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Abstract
Objective—The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
(GUIDE-IT) Study was designed to determine the safety, efficacy, and cost effectiveness of a
strategy based on achieving and maintaining an amino-terminal pro-B-type natriuretic peptide
(NT-proBNP) target of less than 1000 pg/mL, compared with usual care in high risk systolic heart
failure (HF) patients.
Background—Elevations in natriuretic peptide (NP) levels provide key prognostic information
in patients with HF. Therapies proven to improve outcomes in HF patients are generally associated
with decreasing levels of NPs, and observational data show that decreases in NP levels over time
are associated with favorable outcomes. Results from smaller prospective randomized studies of
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this strategy thus far have been mixed, and current guidelines do not recommend serial
measurements of NPs to guide therapy in HF.
Methods—GUIDE-IT is a prospective, randomized, controlled, unblinded, multicenter clinical
trial that aims to randomize approximately 1100 subjects with high risk systolic HF (left
ventricular ejection fraction [LVEF] ≤ 40%) to either usual care (optimized guideline
recommended therapy) or a strategy of adjusting therapy with the goal of achieving and
maintaining a target NT-proBNP target of <1000 pg/mL. Patients in either arm of the study are
followed at regular intervals and after treatment adjustments for a minimum of 12 months. The
primary end-point of the trial is time to cardiovascular death or first HF hospitalization. Secondary
end points will include time to cardiovascular death and all-cause mortality, cumulative mortality,
health related quality of life, resource utilization, cost effectiveness, and safety.
Conclusions—The GUIDE-IT study is designed to definitively assess the effects of a NP guided
strategy in high risk systolic HF patients on clinically relevant end points of mortality,
hospitalization, quality of life, and medical resource use.
Keywords
Heart Failure; Biomarkers; Clinical Trial
Introduction
Heart failure (HF) is a public health problem of massive proportions in both developed and
developing countries (1). In the United States alone, over 5 million patients are estimated to
have HF, more than 1 million hospitalizations and 270,000 deaths result annually from HF,
and disease management accounts for over $30 billion in total costs per annum (2). Evidence
based therapies such as β-blockers and renin-angiotensin-aldosterone system (RAAS)
inhibitors can significantly improve outcomes in HF, but available data suggest that many
patients in clinical practice are either not treated with these agents or are treated with
substantially lower than recommended doses (2-7).
What accounts for this underutilization of cardiac medications of proven benefit? Signs and
symptoms suggestive of disease progression in HF may be subjective and subtle, and under-
recognized by providers and patients (8). Additionally, “therapeutic inertia”—the reluctance
on the part of both patients and providers to increase or modify therapy in face of apparent
clinical stability and the additional follow-up required—may also play a role (9).
A variety of disease management strategies have been evaluated to improve the management
of chronic HF patients, ranging from nursing-based interventions to technologically complex
interventions using implantable hemodynamic monitors and telemedicine. The success of
these approaches has been highly variable, and many are personnel intensive, complex, or
costly to implement (10-12). Therefore, there is a need for a cost effective and objective
measure of disease stability that can be used to favorably impact care of chronic HF patients
and demonstrate improvements in outcomes (13).
The natriuretic peptides (NP), specifically B-type natriuretic peptide (BNP) and amino-
terminal pro-B-type natriuretic peptide (NT-proBNP), provide a readily evaluable objective
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biochemical marker that reflects many aspects of HF physiology and disease progression. It
is well established that the NPs are among the most powerful predictors of adverse outcomes
in HF (14-17). Concentrations decline in response to use of guideline-recommended HF
therapies (Table 1), and rising levels portend poor patient outcomes (18-22). These
observational data have led to the hypothesis that serial measurements of natriuretic peptides
may be used to guide titration of chronic medical therapy in HF.
Previous clinical trials of varying size and design have tested this hypothesis over the last
two decades, with mixed results (Table 2) (23-32). While pooled analyses of these studies
indicate a 20-25% reduction in mortality with biomarker guided therapy, generalizability has
been limited by the small size of studies as well as significant heterogeneity in the inclusion
criteria, treatment strategies, and NP cut-points (33, 34). In light of this uncertainly, current
guidelines do not recommend the use of serial measurements of NP to guide titration of
therapy in HF (2). Thus, the GUIDing Evidence Based Therapy Using Biomarker
Intensified Treatment in Heart Failure (GUIDE-IT) trial was designed to prospectively
evaluate the efficacy of a biomarker-guided HF treatment strategy compared to optimal
medical therapy alone, in a large cohort of high risk patients with systolic HF. GUIDE-IT is
funded by the National Heart Lung and Blood Institute (www.clinicaltrials.gov identifier
NCT01685840) and will be the largest study of biomarker-guided therapy in HF performed
to date.
Methods
Study Objectives
The primary objective of GUIDE-IT is to determine the efficacy and safety of a strategy of
biomarker-guided therapy compared with optimized care in high risk HF patients with left
ventricular systolic dysfunction. The primary endpoint is time to cardiovascular death or
first HF hospitalization. The secondary objectives of GUIDE-IT are to evaluate the effect of
biomarker-guided therapy on hospitalizations, all-cause mortality, cardiovascular death,
resource use, quality of life, cost, and cost-effectiveness.
Study Population
The GUIDE-IT study intends to enroll approximately 1100 patients in with known systolic
HF (LVEF ≤ 40%) and high risk for HF events at sites in the United States and Canada.
Inclusion and exclusion criteria are summarized in Table 3. Patients are considered high risk
if they have had a HF hospitalization, emergency department visit for HF, or were treated
with intravenous diuretics as an outpatient within the prior 12 months, AND an NT-proBNP
>2000 pg/mL or BNP>400 pg/mL at any time during the 30 days prior to randomization.
Patients must also have an LVEF of ≤40% determined by an accepted imaging method
within 12 months prior to randomization.
Study Design
The overall scheme of GUIDE-IT is shown in Figure 1. The trial is a multicenter,
prospective, randomized, parallel control group, unblinded, 2-arm clinical trial comparing
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biomarker-guided therapy to usual care in high risk patients with systolic HF. Patients
enrolled in GUIDE-IT are randomized in a 1:1 allocation to either:
• Usual Care: Titration of HF therapy based on target doses from current evidence
basedguidelines for the management of HF (2)
OR
• Biomarker-Guided: Titration of HF therapy using guideline recommended
therapies (Table 4) with a goal of achieving and maintaining a target NT-proBNP
<1000 pg/mL.
Usual Care
Patients receive care based on the 2013 AHA/ACC guideline recommendations (2).
Investigators are provided with specific information on evidence-based target doses of
neurohormonal antagonists. Diuretics are titrated based on the clinical judgment of the
treating physician. Importantly, routine assessment of NPs will not be performed in the usual
care group except for compelling medical reasons, consistent with current guidelines (2).
Follow-up visits are identical to the schedule of visits for the biomarker-guided arm,
including interim visits when medication changes relevant to the treatment of HF occur.
Biomarker-Guided Arm
While both BNP and NT-proBNP are widely clinically available and have been used in
previous trials of biomarker-guided therapy, NT-proBNP was selected as the marker to
guide therapy in the GUIDE-IT study. The rational for this was that NT-proBNP has a
longer half-life (6 hours vs. 20 minutes), a better ability to predict long-term morbidity and
mortality in a head-to-head comparison in Val-HeFT, and stronger data supporting the
validity of a specific natriuretic peptide target (35). The target of 1000 pg/mL was selected
on the basis of prior data suggesting an inflection point in the risk curve at this
concentration, as well as the favorable results of the PROTECT (Pro-BNP Outpatient
Tailored Chronic HF Therapy) study using the same cut-point (16,28,36).
In the biomarker guided arm, NT-proBNP levels are ascertained at a local laboratory and
utilized by treating physicians for the purpose of achieving values of less than 1000 pg/mL.
The GUIDE-IT protocol specifies interventions to be considered to lower NT-proBNP levels
in the biomarker-guided arm, but specific treatment decisions are at the discretion of the
treating physician (Table 4). The order of implementation is based on clinical judgment,
with more than one intervention allowed during a single encounter. Titration of
neurohormonal antagonists are emphasized over titration of diuretics due to a mortality
benefit of such agents, except in the case of clinically apparent congestion or in the case of
very high NT-proBNP levels (>5000 pg/mL).
Follow-up Visits
For patients in either arm of the study, follow up visits occur 2 weeks after randomization
and subsequently every 3-month basis for the duration of the study once optimal doses of
therapies have been achieved. For patients in either arm of the study, there is a 2-week
follow-up visit after a change in therapy for HF. These post-change in therapy follow-up
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visits usually occur as a face-to-face encounter, but can also be done via a “laboratory only”
visit to reduce patient hardship, at the discretion of the treating physician. Follow-up visits
continue every 2 weeks until therapeutic targets are reached, or the investigator determines
that further titration of therapy is not possible. Patients hospitalized for HF during the study
have a 2-4 week follow-up study visit post discharge to reassess and adjust medical therapy,
which includes all standard follow-up assessments as defined above.
Study Duration and End Points
The anticipated study duration is approximately 5 years; 6 months of start-up activities (i.e.,
finalizing of protocol, preparing study sites and contracts, and receiving site Institutional
Review Board [IRB] approval), 36 months of active enrollment, 12 months of patient
follow-up after the final patient is enrolled, and 6 months of study close-out, data analysis,
and reporting of results.
The primary end point for the GUIDE-IT study is time to CV death or first HF
hospitalization (Table 5). To minimize potential bias in an unblinded study, a Clinical Event
Committee (CEC) blinded to treatment assignment adjudicates all deaths and
hospitalizations. The components of the primary endpoint will also be considered separately
in secondary analyses. Important secondary endpoints include cumulative morbidity,
assessed by recurrent hospitalizations and total days alive and out of the hospital during
follow-up. Other secondary endpoints will include measures of qualify of life (QOL),
resource utilization, cost, and cost effectiveness. An Economic and Quality of Life (EQOL)
core will perform all QOL and economic analyses. QOL assessments will be performed at
baseline, 3 months, 6 months, and then annually to a maximum of 24 months. Assessments
at each visit will include the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Duke
Activity Status Index (DASI), the Epidemiological Studies Depression Scale (CES-D), the
Medical Outcomes Study Short Form (SF-12), the Medical Outcomes Study Short Form
(SF-36) subscales, and the EQ-5D.
In addition to routine safety reporting of adverse events, events that could be related to the
risks of aggressive titration of HF medications (hypotension, bradycardia, renal dysfunction,
and hyperkalemia) will be specifically monitored and reported.
Quality of Life Assessments
Statistical Analysis
All major treatment comparisons between the randomized groups will be performed
according to an intention-to-treat basis. Statistical comparisons of the two randomized arms
with respect to the primary endpoint will be a time-to-event analysis (time from
randomization to the first occurrence of CV death of HF hospitalization). The Cox
proportional-hazards regression model will be the primary tool to assess the effect of
biomarker guidance versus usual care on both the composite outcome, as well as each
component. An adjusted model will be utilized for the primary efficacy analysis in order to
maximize the precision of the estimate of treatment effect (37). The model will include an
indicator variable for treatment group, and the following baseline variables: age, gender,
NT-proBNP, diabetes mellitus, and LVEF. These variables were selected based on their
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known association with outcomes in heart failure as well as the expectation of very little
missing data for these variables. To avoid any potential for bias, the functional form of each
adjustment variable will be prespecified in the statistical analysis plan. In subgroup analyses,
we will examine the effect according to specific patient characteristics. The effect of the NT-
proBNP-guided treatment strategy on all endpoints will be summarized using hazard ratios,
with associated confidence intervals. For analysis of the total days alive and out of hospital
endpoint, we will apply the inverse probability weighted estimators to account for potential
bias due to censored and incomplete data (38).
Statistical Power and Sample Size
Sample size for this study (N=1100) has been selected based on the primary end point, time
to CV death or first HF hospitalization. Based on the anticipated patient population and
recently published clinical trial data, we have projected a 1 year CV-death and
hospitalization rate of 40% for subjects randomized to the usual care arm (27,39). A meta-
analysis by Felker et al. found an aggregate reduction of about 30% in all-cause mortality
with biomarker-guided therapy, so the impact of biomarker-guided therapy can be
conservatively expected to reduce the primary composite endpoint by 20% (33). If we
account for reasonable estimates of drop-in and drop-out (5% for each over 2 years), loss to
follow up (4% per year), and non-CV death (4% per year), 1100 subjects will provide
approximately 90% power to detect a 20% relative reduction (from 40% to 32%) in the
primary endpoint with biomarker guided therapy. Also, GUIDE-IT has a fixed sample size
design with the flexibility of an event driven study design. For secondary endpoints,
assuming at least 350 subjects per treatment group, the study will have >90% power for
detecting a treatment differences of 1/4 standard deviation in secondary end points.
Natriuretic Guided Treatment in the Elderly
Two prior studies (TIME-CHF and BATTLESCARRED; Table 2) suggested a differential
benefit of natriuretic guided treatment according to age, with elderly patients (≥ 75 years)
deriving less benefit; however, other studies such as PROTECT have not reproduced these
findings (26-28). As a result of the lack of clarity surrounding this question, and given that
HF is primarily a disease of the elderly, the differential effect of NP guided treatment based
on age will be examined in GUIDE-IT. We have pre-specified an interaction analysis, with
the population stratified at age 75 years, and determined that we will have adequate power to
detect statistically significant interactions.
Data and Safety Monitoring Board Reviews
The NHLBI-appointed Data and Safety Monitoring Board (DSMB) will meet every 6
months to review the accumulating data. Prior to each meeting, the coordinating center will
conduct any requested statistical analyses and prepare a summary report along with the
following information: patient enrollment reports, rates of compliance with the assigned
testing strategy, frequency of protocol violations, and description of SAEs. For futility
monitoring, the study will apply the inefficacy monitoring rule of Freidlin, Korn, and Gray
to stop the trial if the biomarker-guided strategy is not beneficial (40). We plan to use the
conservative boundary LIB0 along with a harm look at 25% of expected information,
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including 7 interim looks scheduled at roughly 25%, 40%, 50%, 60%, 70%, 80%, and 90%
trial completion. With the proposed design, a total of roughly 566 events are expected and
the first interim review for futility and efficacy would be scheduled to occur after
approximately 140 primary endpoint events have been observed. If the data suggested a
benefit for the usual care arm with a P-value of <0.05, this approach would suggest stopping
the trial at the 25% look. For the interim reviews at 40%, 50%, 60%, 70%, 80%, and 90%,
the LIB0 conservative boundary would suggest stopping the trial for inefficacy if the
biomarker-guided arm had a hazard ratio > 1.0 compared to usual-care arm. Lastly, an
interim efficacy analyses will also be performed (41,42).
Trial Organization
An overview of trial organization is displayed in Figure 2. The study is conducted under the
leadership of an Executive Committee comprised of cardiologists with extensive experience
caring for patients with HF that has overall responsibility for study conduct. The clinical
coordinating center (CCC), data coordinating center (DCC), and economics and quality of
life cores are at the Duke Clinical Research Institute (DCRI). Given the importance of
investigator adherence to the study protocol in order to successfully test the primary
hypothesis, a Protocol Adherence Committee oversees investigator adherence with the study
protocol. Specifically, investigators record their rationale for specific adjustments of HF
medications at each encounter in the case report form. If investigators choose not to
intensify therapy at a given patient visit in the biomarker guided arm despite an NT-proBNP
level >1000 ng/mL, they record their clinical rationale for not making adjustments (e.g,
hypotension limits further up-titration). The Adherence Committee reviews data on the
extent to which investigators are responding to NT-proBNP levels >1000 ng/mL in the
biomarker guided arm and perform educational interventions with investigators in need of
additional training. If investigator adherence is persistently poor at a given site, the
Adherence Committee may recommend halting enrollment at that site.
Core Laboratories and Sub-studies
In order to understand the mechanisms underlying the treatment effect of biomarker guided
therapy (if any), core laboratories for biomarkers, genetics, and echocardiography have been
established. At each clinical encounter, local laboratories are used for NT-proBNP
assessments (biomarker guided arm only), but an additional plasma sample for centralized
NT-proBNP testing is submitted to the biomarker core lab. These values are not transmitted
back to investigators, but used to validate the results of local laboratory testing, as well as to
provide NT-proBNP data on patients in the usual care arm at the conclusion of the study. In
addition, DNA samples as well as serial plasma and serum samples are collected and stored
at a central biomarker-genetics core laboratory for future use. An echocardiographic sub-
study is performing baseline and 12-month echocardiograms on a subset of patients; these
images are interpreted centrally by a core laboratory blinded to treatment allocation or other
clinical data.
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Discussion
Existing clinical guidelines for treatment of chronic systolic HF recommend that therapies
be titrated to target doses from clinical trials, or maximally tolerated doses (2). This is unlike
management of most chronic diseases that utilize a paradigm of therapeutic titration based
on ‘biomarker’ targets known to be associated with patient outcomes; for example,
hemoglobin A1C for diabetes and viral load for HIV. In HF, NPs have emerged as important
biochemical gauges of disease state, with both baseline and serial levels having important
prognostic value (22,34,43,44). However, since a landmark study in 2000 showed dramatic
benefits with NP guided treatment of HF, several randomized trials that differed
considerably in design and execution, have yielded varied results. Meta-analyses of these
studies have determined that using NP levels to guide therapy in chronic systolic HF patients
may lead to significant improvements in clinical outcomes, but these conclusions are
susceptible to known limitations of meta-analyses in the face of small heterogeneous trials
(33,34,44,45).
GUIDE-IT has attempted to incorporate lessons learned from prior studies about how best to
apply NP guided therapy to high risk HF patients (43). First, since the advantages of NP
guidance are limited by the benefits of specific HF therapies, it stands to reason that
biomarker-guided therapy is most likely to be efficacious in patients in whom medical
therapy is known to be effective. Therefore, we have focused on patients with systolic HF
and not included patients with HF and preserved ejection fraction (HFpEF), given the lack
of effective therapeutics for this group of patients. Second, many prior studies with neutral
results may have set natriuretic peptide goals that were too high (i.e., not aggressive
enough), potentially leaving patients “at target” but still with a persistent amount of residual
risk (28,30). For GUIDE-IT, we have adopted the target of 1000 pg/mL, successfully used in
the PROTECT study; while a significant percentage of patients may not achieve this value,
data have indicated that even modest lowering of NT-proBNP and even intermittent periods
of time at or below 1000 pg/mL is associated with superior outcomes compared to those
with less reductions of the biomarker (28,46). Thus, while it would be desirable to reach the
goal in every study participant, a concerted effort to produce reduction in NT-proBNP is
hypothetically likely to produce favorable results. Third, while treating physicians in the
biomarker guided arm will retain responsibility for specific treatment decisions, we will
emphasize up-titration of therapies that have been shown to have mortality benefits such as
β-blockers and RAAS antagonists over diuretics: trials emphasizing use of neurohormonal
antagonists were more likely to show efficacy. Fourth, some prior studies have suggested a
differential treatment effects of a biomarker-guided strategy by age, with greater efficacy in
younger patients (34). For this reason, we pre-specified age (≥75 or < 75 years of age) as a
key subgroup of interest, and GUIDE-IT adequately powered to examine this interaction
appropriately.
GUIDE-IT will be an unblinded trial because blinding would eliminate one potentially
important mechanism of treatment effect: the impact of patient knowledge of their own
natriuretic peptide levels on adherence and health-related behaviors. Blinding GUIDE-IT
would remove the patient from the critical role of active partnership in the management of
his or her disease and would not reflect how biomarker-guided therapy will ultimately be
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used in practice, thus raising important issues about generalizability. We have taken multiple
steps to minimize potential biases related to lack of blinding, including the use of an
objective primary endpoint (cardiovascular death or HF hospitalization), and centralized
adjudication of events by a Clinical Event Committee blinded to treatment assignment.
The GUIDE-IT study is primarily designed to determine the efficacy of a strategy of
biomarker-guided therapy compared with optimized medical care on clinical outcomes in
high-risk patients with systolic HF. However, data from the trial may also clarify several
other important unanswered questions. For example, it is unknown whether the hypothesized
mortality benefits derived from aggressive attempts at lowering biomarker levels could
occur at the expense of increased morbidity related to side effects of therapy, especially
among elderly patients. The Economics and Quality of Life (EQOL) core laboratory will use
a battery of validated instruments such as the Kansas City Cardiomyopathy Questionnaire
that provide a comprehensive assessment of health-related quality of life and allow for
assessment of differences in these measures between treatment arms. The EQOL laboratory
will also collect wide-ranging economic data, thereby allowing for an evaluation of resource
utilization and cost-effectiveness of a biomarker-guided strategy. This inclusion of detailed
quality of life analysis and robust health economic measures will serve to enhance the
overall value of the findings from GUIDE-IT. Furthermore, a robust bio-repository and
echocardiography sub-study will be included and will provide insight into the mechanistic
underpinnings of any observed impact of biomarker-guided therapy on clinical outcomes.
Conclusion
Numerous studies have found that elevations in the NPs are among the best predictors of
adverse outcomes in patients with chronic systolic HF, and that use of guideline-based
therapies is associated with a decrease in serial plasma levels of these markers. The results
of several observational studies and small randomized controlled trials have suggested that a
biomarker-guided strategy aimed at decreasing NP levels, compared with standard care, may
lead to improvements in outcomes among patients with chronic systolic HF. The GUIDE-IT
study is designed to provide the definitive answer about the safety, efficacy, and cost
effectiveness of natriuretic peptide-guided therapy for treatment of chronic systolic HF.
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Abbreviation List
HF Heart Failure
NP Natriuretic Peptides
BNP B-type natriuretic peptide
NT-proBNP Amino terminal pro-B-type natriuretic peptide
RASS Renin-angiotensin-aldosterone system
EQOL Economic and Quality of Life
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DCC Data Coordinating Center
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Figure 1. Schematic diagram for the GUIDing Evidence Based Therapy Using Biomarker
Intensified Treatment in HF (GUIDE-IT) trial
GUIDE-IT aims to randomize approximately 1100 high risk chronic heart failure patients
with left ventricular ejection fraction ≤ 40% to either optimized guideline recommended
therapy or a strategy of adjusting therapy with the goal of achieving and maintaining a target
NT-proBNP target of <1000 pg/mL. Patients in either arm of the study are followed at
regular intervals and after treatment adjustments for a minimum of 12 months. Assessments
during these visits are delineated in the figure.
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Figure 2. Trial Organization
The study is being conducted under the leadership of an Executive Committee comprised of
cardiologists with extensive experience caring for patients with HF that has overall
responsibility for study conduct. The Duke Clinical Research Institute will house the clinical
coordinating center (CCC), data coordinating center (DCC), and economics and quality of
life cores are at the Duke Clinical Research Institute (DCRI).
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Table 1
Therapies for HF That May Lower Natriuretic Peptide Values
Diuresis (loop or thiazide) ↓
Angiotensin-converting enzyme inhibitors ↓
Angiotensin receptor blockers ↓
β-Blockers Transient ↑, mostly ↓
Mineralocorticoid receptor antagonists ↓
Cardiac resynchronization therapy ↓
Exercise ↓
Rate control of atrial arrhythmia ↓
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Table 3
GUIDE-IT Primary Inclusion and Exclusion Criteria
Inclusion Criteria
 Age≥ 18 years
 HF event in Prior 12 months*
 Recent documented LVEF ≤ 40% by any method within 12 months prior to randomization
 BNP > 400 pg/mL or NT-proBNP > 2000 pg/mL in 30 days prior to randomization
Exclusion Criteria
 Clinical diagnosis of ACS† or cardiac revascularization within 30 days
 CRT within prior 3 months or current plans to implant CRT device
 Severe stenotic valvular disease
 Anticipated OHT or VAD within 12 months
 Chronic inotropic therapy
 Complex congenital heart disease
 ESRD with renal replacement therapy
 Non cardiac terminal illness with expected survival less than 12 months
 Women who are pregnant or planning to become pregnant
 Inability to comply with planned study procedures
 Enrollment or planned enrollment in another clinical trial
*A HF Event in the prior 12 months is defined as any one of the following: (a) HF hospitalization (b) Treatment in the emergency department (or
equivalent) for HF (c) Outpatient treatment for HF with intravenous diuretics.
†
Diagnosis of ACS should not depend entirely on positive cardiac markers, as this can be noted in acute HF patients.
BNP indicates B-type natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; ACS, acute coronary syndrome; CRT,
chronic resynchronization therapy; OHT, orthotropic heart transplantation; VAD, ventricular assist device; ESRD, end stage renal disease.
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Table 4
Potential Interventions to Decrease NT-proBNP Levels
Up-titrate or add Angiotensin Converting Enzyme (ACE)-inhibitor or Angiotensin II Receptor Blockers (ARB)
Up-titrate or add beta-blocker (if not clinically congested)
Up-titrate or add hydralazine-nitrates in African-American patients
Increase loop diuretic dosage (if clinically congested or NT-proBNP > 5000 pg/mL)
Add oral thiazide diuretic
Add digoxin
Consider adding ARB to ACE-I (if not on spironolactone)
Consider optimization of cardiac resynchronization therapy (if CRT device implanted)
Up-titrate or add spironolactone if tolerated by renal function and potassium
Consider hydralazine-nitrates in non-African-American patients
Intensified or repeated HF education regarding diet, sodium restriction, etc.
Reconsider potential indications for CRT (if not previously implanted)
If in atrial fibrillation, maximize rate control or consider more aggressive attempts at normal sinus rhythm
Consider exercise training or cardiac rehabilitation
NT-proBNP indicates amino-terminal pro-b-type natriuretic peptide N, number; CRT, chronic resynchronization therapy.
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Table 5
Trial End Points
Primary End Point
 Time to CV death or first HF hospitalization
Secondary End Points
 Time to all-cause mortality
 Days alive and not hospitalized for CV reasons
 Recurrent hospitalizations
 Time to CV death
 Time to first HF hospitalization
 HRQOL
 Resource utilization, cost and cost effectiveness
 Safety
CV indicates cardiovascular; HF, HF; HRQOL, health related quality of life.
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